Shared immunological targets in the lungs and joints of patients with rheumatoid arthritis: Identification and validation

Annals of the Rheumatic Diseases

Volumn 74, Issue 9, 2015, Pages 1772-1777

  Ytterberg, A J ^a,b   Joshua, Vijay ^a   Reynisdottir, Gudrun ^a   Tarasova, Nataliya K ^b   Rutishauser, Dorothea ^b   Ossipova, Elena ^a   Haj Hensvold, Aase ^a   Eklund, Anders ^a   Skold C M ^a   Grunewald, Johan ^a   Malmström, Vivianne ^a   Jakobsson, Per Johan ^a   Rönnelid, Johan ^c   Padyukov, Leonid ^a   Zubarev, Roman A ^b   Klareskog, Lars ^a   Catrina, Anca I ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; CITRULLINATED ACTIN[62-68]; CITRULLINATED ANNEXIN A2[47-65]; CITRULLINATED CYSTEINE RICH PROTEIN 1; CITRULLINATED FIBRINOGEN ALPHA[449-463]; CITRULLINATED FIBRINOGEN ALPHA[559-575]; CITRULLINATED FIBRINOGEN ALPHA[582-599]; CITRULLINATED HEMOGLOBIN SUBUNIT ALPHA; CITRULLINATED HEMOGLOBIN SUBUNIT ALPHA[129-142]; CITRULLINATED HISTONE[25-37]; CITRULLINATED PEPTIDE; CITRULLINATED VIMENTIN[435-455]; CITRULLINATED VIMENTIN[440-445]; CITRULLINATED VIMENTIN[446-466]; CITRULLINATED VIMENTIN[60-75]; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; EPITOPE; HLA DRB1 ANTIGEN; PEPTIDE; UNCLASSIFIED DRUG; AUTOANTIBODY; CITRULLINE; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE; VIMENTIN;

ACCURACY; ADULT; AGED; ALLELE; ANTIBODY PRODUCTION; ANTIGEN ANTIBODY REACTION; ARTICLE; BRONCHUS BIOPSY; CONTROLLED STUDY; DISEASE CONTROL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNITY; IN VIVO STUDY; JOINT; JOINT BIOPSY; LUNG; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN SYNTHESIS; PROTEIN TARGETING; PROTEOMICS; RHEUMATOID ARTHRITIS; SHARED IMMUNOLOGICAL TARGET; SMOKING; VERY ELDERLY; ADOLESCENT; BRONCHUS; CASE CONTROL STUDY; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; SYNOVIUM; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; AUTOANTIGENS; BRONCHI; CASE-CONTROL STUDIES; CITRULLINE; EPITOPES; FEMALE; HLA-DRB1 CHAINS; HUMANS; JOINTS; LUNG; MALE; MASS SPECTROMETRY; MIDDLE AGED; PEPTIDES; PEPTIDES, CYCLIC; PROTEOMICS; SYNOVIAL MEMBRANE; VIMENTIN; YOUNG ADULT;

EID: 84942109702     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204912     Document Type: Article

References (38)

1. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48:2741-9.
2. Nielen MM, van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004;50:380-6.
3. van der Woude D, Rantapaa-Dahlqvist S, Ioan-Facsinay A, et al. Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann Rheum Dis 2010;69:1554-61.
4. Sokolove J, Bromberg R, Deane KD, et al. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS ONE 2012;7:e35296.
5. Brink M, Hansson M, Mathsson L, et al. Multiplex analyses of antibodies against citrullinated peptides in individuals prior to development of rheumatoid arthritis. Arthritis Rheum 2013;65:899-910.
6. van de Sande MG, de Hair MJ, van der Leij C, et al. Different stages of rheumatoid arthritis: features of the synovium in the preclinical phase. Ann Rheum Dis 2011;70:772-7.
7. Klareskog L, Stolt P, Lundberg K, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 2006;54:38-46.
8. Makrygiannakis D, Hermansson M, Ulfgren AK, et al. Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann Rheum Dis 2008;67:1488-92.
9. Demoruelle MK, Weisman MH, Simonian PL, et al. Brief report: airways abnormalities and rheumatoid arthritis-related autoantibodies in subjects without arthritis: early injury or initiating site of autoimmunity? Arthritis Rheum 2012;64:1756-61.
10. Vassallo R, Walters PR, Lamont J, et al. Cigarette smoke promotes dendritic cell accumulation in COPD; a Lung Tissue Research Consortium study. Respir Res 2010;11:45.
11. Reynisdottir G, Karimi R, Joshua V, et al. Structural lung changes and local anti-citrulline immunity are early features of anti citrullinated-proteins antibodies positive rheumatoid arthritis. Arthritis Rheum 2014;66:31-9.
12. Rangel-Moreno J, Hartson L, Navarro C, et al. Inducible bronchus-associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis. J Clin Invest 2006;116:3183-94.
13. Klareskog L, Malmstrom V, Lundberg K, et al. Smoking, citrullination and genetic variability in the immunopathogenesis of rheumatoid arthritis. Semin Immunol 2011;23:92-8.
14. Masson-Bessiere C, Sebbag M, Girbal-Neuhauser E, et al. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. J Immunol 2001;166:4177-84.
15. Vossenaar ER, Despres N, Lapointe E, et al. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther 2004;6:R142-50.
16. Takizawa Y, Suzuki A, Sawada T, et al. Citrullinated fibrinogen detected as a soluble citrullinated autoantigen in rheumatoid arthritis synovial fluids. Ann Rheum Dis 2006;65:1013-20.
17. Pratesi F, Tommasi C, Anzilotti C, et al. Deiminated Epstein-Barr virus nuclear antigen 1 is a target of anti-citrullinated protein antibodies in rheumatoid arthritis. Arthritis Rheum 2006;54:733-41.
18. Kinloch A, Lundberg K, Wait R, et al. Synovial fluid is a site of citrullination of autoantigens in inflammatory arthritis. Arthritis Rheum 2008;58:2287-95.
19. Makrygiannakis D, af Klint E, Lundberg IE, et al. Citrullination is an inflammation-dependent process. Ann Rheum Dis 2006;65:1219-22.
20. Hao P, Ren Y, Alpert AJ, et al. Detection, evaluation and minimization of nonenzymatic deamidation in proteomic sample preparation. Mol Cell Proteomics 2011;10:O111.009381.
21. Reynisdottir G, Karimi R, Joshua V, et al. Structural changes and antibody enrichment in the lungs are early features of anti-citrullinated protein antibody-positive rheumatoid arthritis. Arthritis Rheumatol 2014;66:31-9.
22. Celorio-Mancera Mde L, Sundmalm SM, Vogel H, et al. Chemosensory proteins, major salivary factors in caterpillar mandibular glands. Insect Biochem Mol Biol 2012;42:796-805.
23. Boersema PJ, Foong LY, Ding VM, et al. In-depth qualitative and quantitative profiling of tyrosine phosphorylation using a combination of phosphopeptide immunoaffinity purification and stable isotope dimethyl labeling. Mol Cell Proteomics 2010;9:84-99.
24. Gerber SA, Rush J, Stemman O, et al. Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc Natl Acad Sci USA 2003;100:6940-5.
25. Lundstrom E, Kallberg H, Smolnikova M, et al. Opposing effects of HLA-DRB1∗13 alleles on the risk of developing anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis. Arthritis Rheum 2009;60:924-30.
26. Senshu T, Akiyama K, Kan S, et al. Detection of deiminated proteins in rat skin: probing with a monospecific antibody after modification of citrulline residues. J Invest Dermatol 1995;105:163-9.
27. Holm A, Rise F, Sessler N, et al. Specific modification of peptide-bound citrulline residues. Anal Biochem 2006;352:68-76.
28. Stensland M, Holm A, Kiehne A, et al. Targeted analysis of protein citrullination using chemical modification and tandem mass spectrometry. Rapid Commun Mass Spectrom 2009;23:2754-62.
29. De Ceuleneer M, De Wit V, Van Steendam K, et al. Modification of citrulline residues with 2,3-butanedione facilitates their detection by liquid chromatography/mass spectrometry. Rapid Commun Mass Spectrom 2011;25:1536-42.
30. Tutturen AE, Holm A, Jorgensen M, et al. A technique for the specific enrichment of citrulline-containing peptides. Anal Biochem 2010;403:43-51.
31. Hermansson M, Artemenko K, Ossipova E, et al. MS analysis of rheumatoid arthritic synovial tissue identifies specific citrullination sites on fibrinogen. Proteomics Clin Appl 2010;4:511-18.
32. Darrah E, Rosen A, Giles JT, et al. Peptidylarginine deiminase 2, 3 and 4 have distinct specificities against cellular substrates: novel insights into autoantigen selection in rheumatoid arthritis. Ann Rheum Dis 2012;71:92-8.
33. van Beers JJ, Schwarte CM, Stammen-Vogelzangs J, et al. The rheumatoid arthritis synovial fluid citrullinome reveals novel citrullinated epitopes in apolipoprotein E, myeloid nuclear differentiation antigen, and beta-actin. Arthritis Rheum 2013;65:69-80.
34. Lundberg K, Bengtsson C, Kharlamova N, et al. Genetic and environmental determinants for disease risk in subsets of rheumatoid arthritis defined by the anticitrullinated protein/peptide antibody fine specificity profile. Ann Rheum Dis 2013;72:652-8.
35. Makrygiannakis D, Revu S, Engstrom M, et al. Local administration of glucocorticoids decrease synovial citrullination in rheumatoid arthritis. Arthritis Res Ther 2012;14:R20.
36. Cantaert T, De Rycke L, Bongartz T, et al. Citrullinated proteins in rheumatoid arthritis: crucial...but not sufficient! Arthritis Rheum 2006;54:3381-9.
37. Vossenaar ER, Smeets TJ, Kraan MC, et al. The presence of citrullinated proteins is not specific for rheumatoid synovial tissue. Arthritis Rheum 2004;50:3485-94.
38. Goules JD, Goules AV, Tzioufas AG. Fine specificity of anti-citrullinated peptide antibodies discloses a heterogeneous antibody population in rheumatoid arthritis. Clin Exp Immunol 2013;174:10-17.